Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juanbi pill + methotrexate is a combination therapy consisting of the traditional Chinese medicine Juanbi pill and the disease-modifying antirheumatic drug (DMARD) methotrexate. Juanbi pill is a herbal formula used in China for centuries to treat rheumatoid arthritis (RA), aiming to relieve joint pain and prevent joint malformation. Methotrexate is a folic acid antagonist that inhibits nucleotide synthesis, suppressing inflammation and immune activity. The combination has been studied in randomized controlled trials for active rheumatoid arthritis, with evidence suggesting it may improve disease activity scores, reduce joint inflammation, protect against bone damage, and potentially reduce adverse reactions associated with methotrexate[1][2][3][4]. The primary indication for this combination is active rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on juanbi pill + methotrexate.